What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

Zacks Dec 26 22:40

Arcutis Biotherapeutics Soars on Zoryve Success and Bullish Analyst Ratings

TipRanksDec 18 17:53

Arcutis Submits ZORYVE (Roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 With Mild to Moderate Atopic Dermatitis

GlobeNewswireDec 16 21:00

Express News | Arcutis Submits Zoryve® (Roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 With Mild to Moderate Atopic Dermatitis

BreakingsDec 16 21:00

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Warby Parker (WRBY)

TipRanksDec 16 14:50 · Ratings

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswireDec 7 05:00